Tirzepatide is an injectable medication that produces significant weight loss by activating two gut hormone pathways simultaneously. In the largest clinical trial, people without diabetes lost between 15% and 21% of their body weight over 72 weeks, depending on the dose. It’s sold under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
How Tirzepatide Works
Most weight loss medications in this class target a single gut hormone called GLP-1. Tirzepatide is different because it activates two hormone receptors at once: the GLP-1 receptor and the GIP receptor. Both hormones are naturally released after eating and play roles in blood sugar regulation, insulin production, and appetite signaling. By mimicking both at the same time, tirzepatide reduces hunger, slows stomach emptying, and improves how your body handles insulin.
The way tirzepatide interacts with these two receptors is also unusual at a molecular level. It behaves similarly to the natural GIP hormone at one receptor, but at the GLP-1 receptor it activates signaling in a selective way that causes less receptor “burnout” over time. This may explain why it outperforms drugs that only target GLP-1. The GIP receptor activation also appears to improve insulin sensitivity through a mechanism that’s independent of weight loss itself, which is why tirzepatide is also effective for blood sugar control.
How Much Weight People Lose
The landmark SURMOUNT-1 trial tested tirzepatide in adults with obesity or overweight (without diabetes) over 72 weeks. The results at three dose levels, compared to placebo:
- 5 mg dose: 15% body weight loss
- 10 mg dose: 19.5% body weight loss
- 15 mg dose: 20.9% body weight loss
For someone weighing 250 pounds, the highest dose translates to roughly 52 pounds lost over about a year and a half. These numbers represent averages, so individual results vary. Some people lose more, others less.
In a head-to-head trial published by the New England Journal of Medicine, 751 people with obesity received either tirzepatide or semaglutide (the active ingredient in Wegovy and Ozempic), each at their maximum recommended doses. At 72 weeks, tirzepatide produced 20% weight loss compared to 14% with semaglutide. That six-percentage-point gap is clinically meaningful and represents one of the clearest advantages tirzepatide has shown over existing options.
What the Timeline Looks Like
Treatment starts at a low dose of 2.5 mg per week, which isn’t meant to be a therapeutic dose for weight loss. It’s purely a ramp-up period to let your body adjust and reduce side effects. After four weeks, the dose increases to 5 mg. From there, your prescriber can increase by 2.5 mg increments every four weeks or longer, up to a maximum of 15 mg per week.
Noticeable weight loss typically begins within the first few weeks, though it accelerates as the dose increases. In the SURMOUNT-3 trial, participants who first completed a 12-week intensive lifestyle program (low-calorie diet, exercise, and frequent counseling) lost an average of 6.9% of their body weight during that lead-in period, then lost an additional 21.1% after starting tirzepatide for 72 weeks. That combined approach produced a total average loss of 26.6% from their starting weight.
Common Side Effects
Gastrointestinal symptoms are by far the most frequent issue. Nausea, diarrhea, constipation, stomach discomfort, and acid reflux are all common, particularly during the first weeks on a new dose. These tend to improve as your body adjusts, which is the reason for the gradual dose increases.
Less common side effects include injection site reactions (redness, itching, or mild pain where the needle goes in), heartburn, and vomiting. Some people experience fatigue or dizziness. Most of these are mild to moderate and don’t require stopping treatment, but the GI symptoms are the main reason some people can’t tolerate the higher doses.
Tirzepatide carries a boxed warning, the FDA’s most serious label, related to thyroid tumors. In animal studies, drugs in this class caused thyroid tumors including a type called medullary thyroid carcinoma. It’s not confirmed whether this happens in humans, but the medication is not approved for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2.
What Happens if You Stop
Weight regain after stopping is a real concern and one of the most important things to understand before starting. A systematic review in The BMJ found that after stopping weight management medications, people regain an average of 0.4 kg (just under a pound) per month. All the improvements in metabolic markers like blood pressure, cholesterol, and blood sugar are projected to return to baseline within about 1.4 years of stopping.
This doesn’t mean the medication failed. Obesity is a chronic condition, and tirzepatide works by changing the hormonal signals that drive hunger and fat storage. When the medication stops, those signals return. One trial showed that continuous treatment with a GLP-1 medication sustained weight loss over four years, reinforcing the idea that staying on treatment long term may be necessary to maintain results. This is similar to how blood pressure medication controls hypertension only while you’re taking it.
FDA Approval and Current Guidance
The FDA approved Zepbound (tirzepatide) in November 2023 specifically for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. It’s approved alongside a reduced-calorie diet and increased physical activity, not as a standalone treatment.
In December 2025, the World Health Organization issued its first global guideline on GLP-1 medicines for obesity, naming tirzepatide alongside semaglutide and liraglutide. The WHO recommended these medications for long-term obesity treatment in adults (excluding pregnant women), while noting that the evidence is still limited on long-term safety and what happens after years of use. The guideline also emphasized that structured behavioral interventions, including diet changes and physical activity programs, should accompany medication use, as low-certainty evidence suggests these may enhance outcomes beyond what the drug achieves alone.